News
GSK claims broader 'tissue-agnostic' label for PD-1 drug Jem...
The FDA has approved GlaxoSmithKline's latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the patient population eligible for treatment with the drug.
